These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 12397544)

  • 21. Prevention of sudden cardiac death: a current perspective.
    Domanski MJ; Exner DV
    J Electrocardiol; 1998; 31 Suppl():47-53. PubMed ID: 9988005
    [No Abstract]   [Full Text] [Related]  

  • 22. [What information is given by controlled clinical trials (pharmacological and nonpharmacological) for anti-arrhythmia therapy in the prevention of sudden death?].
    Naccarella F; Croci F
    G Ital Cardiol; 1996 Nov; 26(11):1345-64. PubMed ID: 9036037
    [No Abstract]   [Full Text] [Related]  

  • 23. Sudden cardiac death prevention: antiarrhythmic drugs and the implantable cardioverter-defibrillator.
    Domanski MJ
    J Interv Cardiol; 1995 Feb; 8(1):9-15. PubMed ID: 10155222
    [No Abstract]   [Full Text] [Related]  

  • 24. Pure class III agents for prevention of sudden cardiac death.
    Pratt CM
    J Cardiovasc Electrophysiol; 2003 Sep; 14(9 Suppl):S82-6. PubMed ID: 12950526
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is there a role for amiodarone in the era of the implantable cardioverter-defibrillator?
    Eckardt L; Breithardt G
    Heart Rhythm; 2006 Apr; 3(4):484-7. PubMed ID: 16567301
    [No Abstract]   [Full Text] [Related]  

  • 26. Azimilide. NE 10064, Stedicor.
    Drugs R D; 1999 Apr; 1(4):297-300. PubMed ID: 10566048
    [No Abstract]   [Full Text] [Related]  

  • 27. The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunction: results from the Azimilide Postinfarct Survival Evaluation (ALIVE) trial.
    Pratt CM; Singh SN; Al-Khalidi HR; Brum JM; Holroyde MJ; Marcello SR; Schwartz PJ; Camm AJ;
    J Am Coll Cardiol; 2004 Apr; 43(7):1211-6. PubMed ID: 15063432
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized clinical trials: how long should they last?
    Wellens HJ
    Circulation; 2004 Jul; 110(2):107-8. PubMed ID: 15249514
    [No Abstract]   [Full Text] [Related]  

  • 29. Combination ICD and drug treatments-best options.
    Dorian P
    Resuscitation; 2000 Aug; 45(3):S3-6. PubMed ID: 10959027
    [No Abstract]   [Full Text] [Related]  

  • 30. [The "clinical cost" of implantable cardioverter-defibrillators in the primary prevention of sudden cardiac death should not restrict their use].
    Francia P; Cappato R
    G Ital Cardiol (Rome); 2011 May; 12(5):379-82; discussion 382. PubMed ID: 21593958
    [No Abstract]   [Full Text] [Related]  

  • 31. ICD therapy: what have we learned from the clinical trials?
    Arya A; Haghjoo M; Sadr-Ameli MA
    Heart Lung Circ; 2006 Feb; 15(1):3-11. PubMed ID: 16473784
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Variables of arrhythmia risk in relation to pacemaker and implantable defibrillator].
    Solano A; Oddone D; Croci F; Donateo P; Puggioni E; Brignole M
    Ital Heart J Suppl; 2001 Dec; 2(12):1303-7. PubMed ID: 11838352
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Therapy of hypertrophic cardiomyopathy].
    Cecchi F; Olivotto I
    G Ital Cardiol; 1999 Oct; 29(10):1199-203. PubMed ID: 10546134
    [No Abstract]   [Full Text] [Related]  

  • 34. [Anti-arrhythmic therapy and cardiac failure].
    Cosnay P; Babuty D; Charniot JC; Fauchier L; Fauchier JP
    Arch Mal Coeur Vaiss; 1995 Dec; 88 Spec No 5():35-41. PubMed ID: 8729298
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A benefit-risk assessment of class III antiarrhythmic agents.
    Elming H; Brendorp B; Pehrson S; Pedersen OD; Køber L; Torp-Petersen C
    Expert Opin Drug Saf; 2004 Nov; 3(6):559-77. PubMed ID: 15500415
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Arrhythmias in cardiomyopathies].
    Kaneko Y; Kurabayashi M
    Nihon Rinsho; 2002 Jul; 60(7):1434-9. PubMed ID: 12136626
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Should survivors of myocardial infarction with low ejection fraction be routinely referred to arrhythmia specialists?
    Stevenson WG; Ridker PM
    JAMA; 1996 Aug; 276(6):481-5. PubMed ID: 8691557
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Acute myocardial ischemia and ventricular arrhythmias in the pathogenesis of sudden cardiac death in coronary disease].
    Zehender M; Faber T; Brunner M; Grom A
    Z Kardiol; 2000; 89 Suppl 3():13-23. PubMed ID: 10810781
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amiodarone in congestive heart failure: unravelling the GESICA and CHF-STAT differences.
    Hammill SC; Packer DL
    Heart; 1996 Jan; 75(1):6-7. PubMed ID: 8624874
    [No Abstract]   [Full Text] [Related]  

  • 40. [Clinical therapy for arrhythmias and EBM].
    Otsuka T; Yamashita T
    Nihon Naika Gakkai Zasshi; 2006 Feb; 95(2):234-9. PubMed ID: 16536072
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.